mi-319

MI-319 is a synthetic small molecule MDM2 antagonist designed to disrupt the interaction between MDM2 and p53, thereby stabilizing p53 and restoring its tumor suppressor function in cells with wild-type p53. It is closely related to other MDM2 antagonists such as MI-219 and Nutlin-3, sharing a similar mechanism of action. Preclinical studies have demonstrated that MI-319 shows potent anti-proliferative and pro-apoptotic activity in B-cell lymphoma cell lines and primary patient samples retaining wild-type p53, but not in cells with mutant p53[1][5]. In animal models, MI-319 was well tolerated and significantly increased survival in lymphoma-bearing mice, suggesting potential for further clinical development in p53 wild-type cancers[1]. MI-319 also exhibits synergistic activity with cisplatin in reducing cell viability and inducing apoptosis in pancreatic cancer cells, with effects mediated through p73 in p53 mutant or null contexts[3].

Other names

MI319MI-319MI 319